Acacia Pharma Ltd.
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.acaciapharma.com
US Phase III Study of APD421 in PONV
- Conditions
- PONV
- Interventions
- Drug: APD421- Amisulpride for IV injectionDrug: Placebo
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 364
- Registration Number
- NCT01991860
- Locations
- 🇺🇸
Duke, Durham, North Carolina, United States
European Phase III Study of APD421 in PONV
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 368
- Registration Number
- NCT01991821
- Locations
- 🇫🇷
CHU de Hautepierre, Strasbourg, France
🇩🇪University Hospitals of Würzburg, Würzburg, Germany
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
- Conditions
- CINV
- Interventions
- Drug: PlaceboDrug: APD403 IVDrug: APD403 oral
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 342
- Registration Number
- NCT01857232
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
Phase II Dose-ranging Study of APD421 in PONV
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 215
- Registration Number
- NCT01510704
- Locations
- 🇫🇷
University Hospital, Nancy, France
🇩🇪Klinikum Ludwigshafen, Ludwigshafen, Germany
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Proof-of-concept (PoC) Study of APD515
- Conditions
- Xerostomia in Advanced Cancer Patients
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT01331746
- Locations
- 🇬🇧
Sue Ryder Leckhampton Court Hospice, Cheltenham, United Kingdom
🇬🇧Coventry and Warwickshire Partnership Trust, Coventry, United Kingdom
🇬🇧Royal Surrey County Hospital, Guildford, United Kingdom
Phase II Proof-of-concept Study of APD421
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 51
- Registration Number
- NCT01303978
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
🇩🇰Herlev Hospital, Copenhagen, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
Pilot Study of APD209 in Cancer Cachexia
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT00895726
- Locations
- 🇬🇧
Royal Infirmary Edinburgh, Edinburgh, United Kingdom
Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 257
- Registration Number
- NCT00895830
- Locations
- 🇫🇷
Hôpital Huriez, Lille, France
🇩🇪University of Leipzig, Leipzig, Germany
🇩🇪Klinikum Ludwigshafen, Ludwigshafen, Germany